DigiLab Harvard Researchers Snag $300K NIH Grant to Develop Single-Cell Array to Study Bacteria Premium The National Institutes of Health has awarded a team of Harvard University researchers nearly $300,000 to develop a new microarray platform capable of imaging millions of bacterial cells in an overnight experiment. Pressure Bio, Digilab Join in Co-marketing, R&D Effort VCs, Researchers, Vendors Agree: When It Comes to Funding, Arrays Face Difficult Times Premium By Justin Petrone Axela Taps Digilab to Market Array Analysis Systems to US Customers Premium Under the terms of the deal, Holliston, Mass.-based Digilab will sell Axela's Ziplex system for gene and protein expression analysis and dotLab mX system for real-time immunoassays. Digilab Marketing Axela Instruments The deal calls for Digilab to market new versions of Axela's proprietary flow-through technologies, the Ziplex system and the dotLab mX system. Jul 13, 2011 DigiLab Moves Into Live and Stem-Cell Research Market with Launch of CellJet Arrayer Premium Breaking News Gastric Cancer Chemotherapy Response, Prognoses Predicted With Blood-Based Immune Proteomics International Commission to Expand Molecular Testing Access for Cancer Patients NYU Langone Perlmutter Cancer Center to Validate Biological Dynamics Pancreatic Cancer Test SomaLogic Expands Into Middle East With Proteomics Supply Deal for Group 42 Healthcare Arima Genomics to Offer NGS-Based Gene Fusion Test Through Protean BioDiagnostics CLIA Lab The Scan Drug Response Variants May Be Distinct in Somatic, Germline Samples Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline. Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine. Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures. Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.